Claudia C. Wagner

Paul Ehrlich Str. 15
Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Generation of a highly versatile TCR bispecific scaffold optimized for targeting tumor-specific peptide-HLA antigens.

Generation of a highly versatile TCR bispecific scaffold optimized for targeting tumor-specific peptide-HLA antigens.

Journal: mAbs

Published: September 01, 2026

Author Correction: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.

Author Correction: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.

Journal: Nature medicine

Published: April 29, 2025

Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.

Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.

Journal: Nature medicine

Published: August 05, 2024

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.

Journal: Journal for immunotherapy of cancer

Published: June 21, 2024

An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions.

An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions.

Journal: Scientific reports

Published: January 20, 2023

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.

Journal: Cancer immunology research

Published: September 01, 2022

Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy.

Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy.

Journal: Science translational medicine

Published: August 31, 2022

Inequality and fairness with heterogeneous endowments.

Inequality and fairness with heterogeneous endowments.

Journal: PloS one

Published: March 23, 2022

The future of human behaviour research.

The future of human behaviour research.

Journal: Nature human behaviour

Published: January 28, 2022

Inequality and inequity in network-based ranking and recommendation algorithms.

Inequality and inequity in network-based ranking and recommendation algorithms.

Journal: Scientific reports

Published: September 16, 2021

SARS-CoV-2-reactive T-cell receptors isolated from convalescent COVID-19 patients confer potent T-cell effector function.

SARS-CoV-2-reactive T-cell receptors isolated from convalescent COVID-19 patients confer potent T-cell effector function.

Journal: European journal of immunology

Published: April 02, 2021

Measuring algorithmically infused societies.

Measuring algorithmically infused societies.

Journal: Nature

Published: March 05, 2021

Showing 1-12 of 24

Last Updated: 09/26/2026